Immutep Ltd ADR

Yahoo Finance • 4 days ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels Dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profile Substantial reduction in... Full story

Yahoo Finance • 10 days ago

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

Immutep Limited The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolment Strong operational progress continues globally with over 120 activated clinical sites and 27 countries h... Full story

Yahoo Finance • 11 days ago

Immutep (IMMP) Scores Win After Announcing Deal With Indian Firm

We recently published 7 Best ASX Stocks to Buy Right Now.  Immutep Limited (NASDAQ:IMMP) is one of the best ASX stocks. Immutep Limited (NASDAQ:IMMP) is a biotechnology company developing therapies for cancer and autoimmune diseases. The... Full story

Yahoo Finance • 16 days ago

Immutep Limited (IMMP): Firm Reports Positive Data from Trials

Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.Immutep Limited (IMMP): Firm Reports Positive Data from Trials In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from... Full story

Yahoo Finance • 30 days ago

High Growth Tech Stocks In Australia For November 2025

As the Australian market navigates a period of mixed sentiment, with the S&P/ASX 200 (XJO) rebounding to 8,600 points despite inflation climbing to 3.8%, investors are closely watching sectors like IT which recently lagged behind materials... Full story

Yahoo Finance • 2 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft tissue sarcoma (p<0.001) High level of tumour hyalinization/fibrosis, achieved across multiple STS... Full story

Yahoo Finance • 3 months ago

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep Limited Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysis Over 100 clinical sites across 24 countries now acti... Full story

Yahoo Finance • 4 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited... Full story

Yahoo Finance • 5 months ago

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS &lt;1

Immutep Limited SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it ha... Full story

Yahoo Finance • 5 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster p... Full story

Yahoo Finance • 6 months ago

Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data

Immutep Limited (NASDAQ:IMMP) is one of the 7 Best ASX Stocks to Buy Now. On June 23, Immutep Limited (NASDAQ:IMMP) announced positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind fir... Full story

Yahoo Finance • 2 years ago

10 Best Australian Stocks To Buy

In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To B... Full story

Yahoo Finance • 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Media Release Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes Early incre... Full story

Yahoo Finance • 2 years ago

Immutep to Participate in November Investor Events

SYDNEY, AUSTRALIA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease,... Full story

Yahoo Finance • 2 years ago

Immutep receives ~A$1.13 million R&D Tax Incentive

Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash reba... Full story

Yahoo Finance • 2 years ago

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Media Release Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer continuesStrong 71.4% Overall Response Rate,... Full story

Yahoo Finance • 2 years ago

Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not bee... Full story

Yahoo Finance • 2 years ago

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CESTImmutep to host webcast to discuss ESMO 2023 clinical data o... Full story

Yahoo Finance • 2 years ago

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Media Release SYDNEY, AUSTRALIA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune... Full story

Yahoo Finance • 3 years ago

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announce... Full story